相关实验视频
Updated: Jan 17, 2026

12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.9K
恩福图马布维多丁诱发的牛皮性皮肤炎
Robin Wang1, Kristen Fernandez, Brandon Zelman
1Department of Dermatology, Loyola University Medical Center, Maywood, Illinois, United States. Robin.wang@luhs.org.
Dermatology online journal
|September 24, 2025
概括
恩福图马布维多丁可以引起严重的皮肤反应,如尿路癌患者的牛皮性皮肤炎. 用皮质类固醇和剂量调整的早期干预可以控制毒性,允许继续治疗.
科学领域:
- 在瘤学瘤学.
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 恩福图马布维多丁是一种新型抗体-药物结合物,向尿路癌的nectin-4.
- 皮肤的不良事件是常见的与enfortumab vedotin,可能是由于nectin-4表达在皮肤.
- 结核素-4在尿癌细胞中过度表达,使其成为关键的治疗点.
研究的目的:
- 报告患有Enfortumab vedotin和Pembrolizumab治疗的患者发生严重的牛皮皮炎病例.
- 描述这种毒性的临床和组织病理特征.
- 为了突出对恩福图马布维多丁诱导的皮肤毒性有效的管理策略.
主要方法:
- 一名患有转移性尿路细胞癌的患者接受了恩福图马布 (enfortumab vedotin) 和潘布罗利祖马布 ( pembrolizumab).
- 患者在两次循环后出现了3级牛皮性皮肤炎.
- 组织病理学揭示了带有失色肌肉细胞和死亡肌肉细胞的皮内水泡.
主要成果:
- 这位患者患有3级皮炎,其特征是皮内水泡.
- 暂时停止药物和局部皮质类固醇治疗导致改善.
- 恢复用减少剂量的恩福图马布维多丁,与布罗利祖马布,并没有导致复发.
结论:
- 恩福图马布维多丁可以诱发严重的牛皮性皮肤炎,可能与对表达nectin-4的皮肤细胞的脱效应有关.
- 治疗包括药物中断,局部皮质类固醇,以及潜在的剂量减少以重新开始治疗.
- 这一案例强调了识别和管理与恩福图马布韦多相关的皮肤毒性的重要性.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493

